Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Anti-human vWF monoclonal antibody, AJvW-2 fab, inhibits repetitive coronary artery thrombosis without bleeding time prolongation in dogs
Autore:
Kageyama, S; Yamamoto, H; Nakazawa, H; Yoshimoto, R;
Indirizzi:
Ajinomoto Co Inc, Pharmaceut Res Labs, Dev Res Labs, Kawasaki Ku, Kawasaki, Kanagawa 2108681, Japan Ajinomoto Co Inc Kawasaki Kanagawa Japan 2108681 Kanagawa 2108681, Japan
Titolo Testata:
THROMBOSIS RESEARCH
fascicolo: 5, volume: 101, anno: 2001,
pagine: 395 - 404
SICI:
0049-3848(20010301)101:5<395:AVMAAF>2.0.ZU;2-O
Fonte:
ISI
Lingua:
ENG
Soggetto:
ANTIPLATELET GPIIB/IIIA ANTIBODY; CYCLIC FLOW VARIATIONS; VON-WILLEBRAND-FACTOR; GLYCOPROTEIN-IIB/IIIA RECEPTOR; ACUTE MYOCARDIAL-INFARCTION; SINGLE BOLUS INJECTION; PLATELET-AGGREGATION; VONWILLEBRAND-FACTOR; CANINE MODEL; SHEAR-STRESS;
Keywords:
thrombosis; vWF; platelets; AJvW-2; abciximab; bleeding time;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
28
Recensione:
Indirizzi per estratti:
Indirizzo: Yamamoto, H Ajinomoto Co Inc, Pharmaceut Res Labs, Dev Res Labs, Kawasaki Ku, 1-1 Suzuki Cho, Kawasaki, Kanagawa 2108681, Japan Ajinomoto Co Inc 1-1 Suzuki Cho Kawasaki Kanagawa Japan 2108681
Citazione:
S. Kageyama et al., "Anti-human vWF monoclonal antibody, AJvW-2 fab, inhibits repetitive coronary artery thrombosis without bleeding time prolongation in dogs", THROMB RES, 101(5), 2001, pp. 395-404

Abstract

The antithrombotic and antihaemostatic effects of the monoclonal antibody against human VWF (AJvW-2 Fab) were investigated in comparison with those of the monoclonal antibody against platelet GPIlb/IIIa (abciximab) in dogs. The ex vivo platelet aggregation and template bleeding time were measured before, 5, 90, 210 min and 24 h after injection of either AJvW-2 Fab or abciximab in anesthetized beagle dogs. Plasma concentration, vWF occupancy and plasma VWF antigen level were also measured by ELISA. Ln addition, the antithrombotic effect was evaluated in a canine model of repetitive coronary thrombosis (Folts model). AJvW-2 Fab significantly Inhibited the ex vivo botrocetin-induced platelet aggregation at 0.18 mg/kg (53% plasma VWF occupancy) and also inhibited cyclic flow reductions (CFRs) at 0.06 mg/kg (31% occupancy). A significant prolongation of the bleeding time was observed at 1.8 mg/kg (95% occupancy), which was 30 times as high as the antithrombotic effective dose. Whereas, abciximab significantly inhibited both the ex vivo ADP-induced platelet aggregation and CFRs at 0.8 mg/kg, which was the minimally effective dose, also resulting in a significant prolongation of the bleeding time. These results suggest that blockade of the GPIb-vWF axis with AJvW-2 Fab leads to the inhibition of thrombus formation in the stenosed coronary arteries without less bleeding time prolongation than the GPIIb/IIIa blockade with abciximab. (C) 2001 Elsevier Science Ltd. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/02/20 alle ore 13:02:09